Dow Falls 150 Points; Oracle Posts Downbeat Results
Dow Falls 150 Points; Oracle Posts Downbeat Results
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 150 points on Tuesday.
今天上午美国股市涨跌互现,道琼斯指数周二下跌约150点。
Following the market opening Tuesday, the Dow traded down 0.36% to 44,242.81 while the NASDAQ rose 0.43% to 19,820.91. The S&P 500 also fell, dropping, 0.01% to 6,052.43.
周二开盘后,道琼斯指数下跌0.36%,至44,242.81点,而纳斯达克指数上涨0.43%,至19,820.91点。标准普尔500指数也下跌了0.01%,至6,052.43点。
Leading and Lagging Sectors
Communication services shares jumped by 2.3% on Tuesday.
领先和落后的行业
周二,通信服务股上涨了2.3%。
In trading on Tuesday, utilities shares fell by 1.1%.
在周二的交易中,公用事业股下跌了1.1%。
Top Headline
热门标题
Oracle Corporation (NYSE:ORCL) posted weaker-than-expected earnings and sales results for its second quarter on Monday.
甲骨文公司(纽约证券交易所代码:ORCL)周一公布的第二季度收益和销售业绩均低于预期。
The company reported second-quarter revenue of $14.06 billion, up 9% year-over-year. The revenue total missed a Street consensus estimate of $14.11 billion.
该公司报告第二季度收入为140.6亿美元,同比增长9%。总收入未达到华尔街共识估计的141.1亿美元。
Equities Trading UP
股票交易上涨
- Chimerix, Inc. (NASDAQ:CMRX) shares shot up 172% to $2.36 after the company announced it will submit dordaviprone for accelerated approval to the FDA for patients with recurrent H3 K27M-mutant diffuse glioma.
- Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) got a boost, surging 112% to $2.6400 after the company announced the FDA has approved its supplemental new drug application for acetadote.
- uniQure N.V. (NASDAQ:QURE) shares were also up, gaining 104% to $15.00 after the company announced an agreement with the FDA on key elements of an accelerated pathway for AMT-130.
- Chimerix, Inc.(纳斯达克股票代码:CMRX)股价飙升了172%,至2.36美元,此前该公司宣布将向美国食品药品管理局提交用于复发性H3 K2700万突变弥漫性神经胶质瘤患者的多达维酮,以加速获得美国食品药品管理局的批准。
- 坎伯兰制药公司(纳斯达克股票代码:CPIX)的股价上涨,在该公司宣布美国食品药品管理局已批准其醋酸盐补充新药申请后,该公司股价飙升了112%,至2.6400美元。
- UniQure N.V.(纳斯达克股票代码:QURE)股价也上涨了104%,至15.00美元,此前该公司宣布与美国食品药品管理局就AMT-130加速路径的关键要素达成协议。
Equities Trading DOWN
股票交易下跌
- CervoMed Inc. (NASDAQ:CRVO) shares dropped 75% to $2.54 after the company announced its Phase 2b trial of Neflamapimod failed to meet its key endpoints for the treatment of dementia.
- Shares of Biora Therapeutics, Inc. (NASDAQ:BIOR) were down 44% to $0.7499.
- MEDIROM Healthcare Technologies Inc. (NASDAQ:MRM) was down, falling 41% to $1.65. MEDIROM Healthcare priced its $5 million public offering of 2.86 million American Depositary Shares at $1.75 per ADS.
- CervoMed Inc.(纳斯达克股票代码:CRVO)股价下跌75%,至2.54美元,此前该公司宣布其Neflamapimod的第20期试验未能达到其治疗痴呆症的关键终点。
- Biora Therapeutics, Inc.(纳斯达克股票代码:BIOR)的股价下跌44%,至0.7499美元。
- MediRom Healthcare Technologies Inc.(纳斯达克股票代码:MRM)下跌41%,至1.65美元。Medirom Healthcare将其500万美元的286万股美国存托股票的公开发行定价为每股ADS1.75美元。
Commodities
In commodity news, oil traded up 0.1% to $68.40 while gold traded up 1% at $2,712.20.
大宗商品
在大宗商品新闻方面,石油价格上涨0.1%,至68.40美元,而黄金上涨1%,至2712.20美元。
Silver traded up 0.4% to $32.750 on Tuesday, while copper fell 0.6% to $4.2500.
周二,白银上涨0.4%,至32.750美元,而铜价下跌0.6%,至4.2500美元。
Euro zone
欧元区
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.2%, Germany's DAX rose 0.2% and France's CAC 40 fell 0.6%. Spain's IBEX 35 Index fell 0.1%, while London's FTSE 100 fell 0.6%.
今天欧洲股市大多走低。欧元区斯托克600指数下跌0.2%,德国DAX指数上涨0.2%,法国CAC 40指数下跌0.6%。西班牙的IBEX 35指数下跌0.1%,而伦敦富时100指数下跌0.6%。
Asia Pacific Markets
亚太市场
Asian markets closed mixed on Monday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index gaining 2.76%, China's Shanghai Composite Index falling 0.05% and India's BSE Sensex falling 0.25%.
周一亚洲市场收盘涨跌互现,日本日经225指数上涨0.18%,香港恒生指数上涨2.76%,中国上证综合指数下跌0.05%,印度BSE Sensex下跌0.25%。
Economics
经济学
U.S. nonfarm business sector labor productivity increased by 2.2% in the third quarter, in-line with the preliminary reading.
美国非农商业部门的劳动生产率在第三季度增长了2.2%,与初步数据一致。
Now Read This:
现在阅读这篇文章:
- Amazon To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
- 亚马逊将上涨约15%?以下是周二分析师的十大预测